Literature DB >> 9166035

Profile of non-compliance in lymphoblastic leukaemia.

D Lancaster1, L Lennard, J S Lilleyman.   

Abstract

A nationwide study of intracellular drug metabolite concentrations in children prescribed 6-mercaptopurine for the treatment of lymphoblastic leukaemia was carried out to assess interpatient variability at a standardised dose. Nine children (2% of the total) had completely undetectable metabolites, indicative of non-compliance. Five were adolescents, but otherwise they had no obvious distinguishing characteristics. Not taking any 6-mercaptopurine at all is uncommon, but the problem cannot be predicted. The total number of children who do not comply cannot be determined from this study, but the nine children described represent only a fraction of these.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9166035      PMCID： PMC1717135          DOI： 10.1136/adc.76.4.365

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


  5 in total

1.  Non-compliance with oral chemotherapy in childhood leukaemia.

Authors:  J S Lilleyman; L Lennard
Journal:  BMJ       Date:  1996-11-16

2.  Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.

Authors:  L Lennard; J S Lilleyman
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

3.  Compliance of pediatric and adolescent cancer patients.

Authors:  C K Tebbi; K M Cummings; M A Zevon; L Smith; M Richards; J Mallon
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

4.  Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.

Authors:  K Schmiegelow; H Schrøder; G Gustafsson; J Kristinsson; A Glomstein; T Salmi; L Wranne
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544

5.  Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance?

Authors:  L Lennard; J Welch; J S Lilleyman
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640
  5 in total
  12 in total

1.  Rethinking Adherence: A Proposal for a New Approach to Risk Assessment.

Authors:  Abby R Rosenberg; Catherine Fiona Macpherson; Leah Kroon; Rebecca Johnson
Journal:  J Adolesc Young Adult Oncol       Date:  2013-06       Impact factor: 2.223

2.  Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis.

Authors:  Yelena P Wu; David D Stenehjem; Lauri A Linder; Bin Yu; Bridget Grahmann Parsons; Ryan Mooney; Mark N Fluchel
Journal:  J Pediatr Oncol Nurs       Date:  2017-11-30       Impact factor: 1.636

3.  A grounded theory of the process of adherence to oral chemotherapy in Hispanic and caucasian children and adolescents with acute lymphoblastic leukemia.

Authors:  Wendy Landier; Cynthia B Hughes; Evelyn R Calvillo; Nancy L R Anderson; Deborah Briseño-Toomey; Leticia Dominguez; Alex M Martinez; Cara Hanby; Smita Bhatia
Journal:  J Pediatr Oncol Nurs       Date:  2011-06-08       Impact factor: 1.636

4.  Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).

Authors:  Michael E Rytting; Deborah A Thomas; Susan M O'Brien; Farhad Ravandi-Kashani; Elias J Jabbour; Anna R Franklin; Tapan M Kadia; Naveen Pemmaraju; Naval G Daver; Alessandra Ferrajoli; Guillermo Garcia-Manero; Marina Y Konopleva; Jorge E Cortes; Gautham Borthakur; Rebecca Garris; Maria Cardenas-Turanzas; Kurt Schroeder; Jeffrey L Jorgensen; Steven M Kornblau; Hagop M Kantarjian
Journal:  Cancer       Date:  2014-07-17       Impact factor: 6.860

Review 5.  Current issues in pediatric medication adherence.

Authors:  Doreen Matsui
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Clinical and laboratory evaluation of compliance in acute lymphoblastic leukaemia.

Authors:  B M de Oliveira; M B Viana; C L Zani; A J Romanha
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

7.  The development of an objective methodology to measure medication adherence to oral thiopurines in paediatric patients with acute lymphoblastic leukaemia--an exploratory study.

Authors:  Ahmed F Hawwa; Jeff S Millership; Paul S Collier; Anthony McCarthy; Sid Dempsey; Carole Cairns; James C McElnay
Journal:  Eur J Clin Pharmacol       Date:  2009-07-28       Impact factor: 2.953

Review 8.  Oral chemotherapy agents in the treatment of leukaemia.

Authors:  R B Geller; S P Dix
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 9.  Psychosocial barriers and facilitators to clinical trial enrollment and adherence for adolescents with cancer.

Authors:  Natasha D Buchanan; Rebecca Block; Ashley Wilder Smith; Eric Tai
Journal:  Pediatrics       Date:  2014-06       Impact factor: 7.124

10.  Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.